CRO Pharmatest Services has announced two new services at the ASBMR annual meeting in Montreal, Canada.
The new offerings included a preclinical mouse model of osteogenesis imperfecta and clinical bone marker measurement.
Pharmatest聽offers preclinical efficacy services in the fields of oncology and skeletal diseases. In skeletal diseases, the company provides bone cell culture models and animal models of osteoporosis and osteoarthritis.
Pharmatest has now widened its portfolio of preclinical efficacy models in skeletal diseases by launching a mouse model of聽osteogenesis imperfecta聽(OI). The model utilises heterozygous (+/G610C) male mice that exhibit a variable form of OI (type IV).
CEO of Pharmatest聽Jussi Halleen comments: 鈥淭he OI model that we are now launching is our first model of rare bone diseases, and it strengthens our position as a CRO offering preclinical efficacy models in skeletal diseases.鈥�
Pharmatest has strong expertise in performing bone turnover marker measurements in its preclinical efficacy models. Pharmatest now launches聽clinical bone marker measurements聽that are performed using the聽iSYS automated platform聽of Immunodiagnostic Systems Plc (IDS).
Research director in the bone marker unit of Pharmatest Katja Fagerlund says: 鈥淲e have a long history in collaborating with IDS and offering bone turnover marker measurements in our preclinical studies. We are now very excited to start offering also clinical bone marker measurements using the IDS-iSYS automated platform.鈥�